Oral vitamin D3 supplementation for chronic plaque psoriasis: A randomized, double-blind, placebo-controlled trial.
J Dermatolog Treat. 2018 Feb 26:1-34. doi: 10.1080/09546634.2018.1444728. [Epub ahead of print]
Ingram MA1, Jones MB2, Stonehouse W3, Jarrett P4,5, Scragg R6, Mugridge O1, von Hurst PR1.
1 School of Sport, Exercise and Nutrition, Massey Univ., Albany Campus , Private Bag 102904 , North Shore City , Auckland 0745 , New Zealand.
2 Institute of Natural and Mathematical Sciences, Massey Univ., Albany Campus , Private Bag 102904 , North Shore City , Auckland 0745 , New Zealand.
3 Commonwealth Scientific and Industrial Research Organisation, Food and Nutrition Flagship , Adelaide , South Australia 5000 , Australia.
4 Department of Dermatology , Middlemore Hospital , Otahuhu , Auckland 1640 , New Zealand.
5 Department of Medicine , The University of Auckland , Auckland 1072 , New Zealand.
6 School of Population Health, The University of Auckland , Auckland 1142 , New Zealand.
- Psoriasis – less frequent and shorter duration with higher vitamin D (45 ng is nice) – Dec 2016
- Psoriasis severity associated with low vitamin D (10 studies) – meta-analysis Jan 2018
- Dermatologists are reminded of the importance of vitamin D in 8 diseases – Oct 2017
- Psoriasis proven to be treated by Vitamin D in many RCT, but dermatologists fear losing business – March 2015
Need a lot more Vitamin D
Topical Vitamin D works well
- Scalp psoriasis – Vitamin D was a component of every successful topical treatment – Cochrane Feb 2016
UV also works well
Purpose The management of psoriasis remains a challenge for dermatologist and patient. This study aimed to determine whether vitamin D3 supplementation improves psoriasis compared to placebo.
Materials and methods In a randomized, doubled-blind, placebo-controlled trial, 101 participants ≥18 years with psoriasis were grouped by severity and allocated to 100,000 International Units (IU) vitamin D3/month for 12 months (200,000 IU at baseline; n = 67) or an identical placebo (n = 34). Psoriasis Area and Severity Index (PASI) and serum 25(OH)D concentrations were assessed at 3-monthly intervals. The primary outcome was the difference in PASI between groups over time. The relationship between 25(OH)D and PASI across the sample was also considered in a post hoc analysis.
Results PASI did not differ between groups at any time (group F(1,104)=0.48, P = 0.49; group*time F(4,384)=0.26, P = 0.90). However, 25(OH)D increased in both groups, rendering these findings inconclusive. A significant inverse relationship existed between PASI and 25(OH)D, with elevation of 25(OH)D by up to 125 nmol/L associated with mild decreases in PASI (estimated range of decrease 0 - 2.6; P = 0.002).
Conclusions A direct benefit of vitamin D3 supplementation for psoriasis could not be determined. However, these findings suggest a relationship between 25(OH)D and psoriasis severity, at least in some subgroups.
PMID: 29480035 DOI: 10.1080/09546634.2018.1444728